Curative Biotechnology, Inc.

Equities

CUBT

US23128N1081

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
0.019 ^USD	-1.04%		-1.55%	-10.80%

06/05	Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	CI

Curative Biotechnology, Inc. Appoints Dr. Catherine Sohn as Special Advisor to Board and CEO

October 12, 2021 at 07:42 pm IST

Curative Biotechnology, Inc. announced that Dr. Catherine Sohn has joined the company as a Special Advisor to the Board of Directors and the CEO. Dr. Sohn is President of Sohn Health Strategies and Adjunct Professor at the University of California, San Francisco, her alma mater, where she received her Doctor of Pharmacy degree and the Distinguished Alumnus Award (2000). Dr. Sohn is currently Chairman of BioEclipse Therapeutics, a privately held, clinical-stage oncology company and is an independent Director on the Board of Directors of Jazz Pharmaceuticals plc, Rubius Therapeutics, Axcella Health, Landec Corp.

and privately held Maze Therapeutics.

Latest news about Curative Biotechnology, Inc.

Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/05	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	25/11	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	07/23/07	CI
Curative Biotechnology, Inc. Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions	07/23/07	CI
Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study	05/23/05	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/22/17	CI
Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.	07/22/07	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.	31/22/31	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	01/22/01	CI
Curative Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	30/22/30	CI
Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors	16/22/16	CI
Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors	12/22/12	CI
Curative Biotechnology, Inc. has filed an IPO.	15/22/15	CI
Curative Biotechnology, Inc. Auditor Raises 'Going Concern' Doubt	15/22/15	CI
Curative Biotechnology Announces Cooperative Research and Development Agreement with the National Eye Institute	21/22/21	CI
Curative Biotechnology, Inc. announced that it has received $1 million in funding	21/22/21	CI
Curative Biotechnology, Inc. announced that it expects to receive $1 million in funding	04/22/04	CI
Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular Degeneration	24/21/24	CI
Curative Biotechnology, Inc. Auditor Raises 'Going Concern' Doubt	24/21/24	CI
Curative Biotechnology, Inc. Appoints Dr. Catherine Sohn as Special Advisor to Board and CEO	12/21/12	CI
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine	07/21/07	CI
Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board	02/21/02	CI
Curative Biotechnology, Inc. has Changed its Ticker to CUBT from CTYX	29/21/29	CI
Curative Biotechnology, Inc. Announces Additions to Scientific and Clinical Advisory Board	29/21/29	CI
Connectyx Technologies Holdings Group, Inc. Announces Management Changes	11/21/11	CI

Chart Curative Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CURATIVE BIOTECHNOLOGY, INC.	-10.80%	17.16M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research